2 research outputs found
Effects of Maresin 1 (MaR1) on Colonic Inflammation and Gut Dysbiosis in Diet-Induced Obese Mice
The aim of this study was to characterize the effects of Maresin 1 (MaR1), a DHA-derived
pro-resolving lipid mediator, on obesity-related colonic inflammation and gut dysbiosis in diet-induced
obese (DIO) mice. In colonic mucosa of DIO mice, the MaR1 treatment decreased the expression
of inflammatory genes, such as Tnf-α and Il-1β. As expected, the DIO mice exhibited significant
changes in gut microbiota composition at the phylum, genus, and species levels, with a trend to a
higher Firmicutes/Bacteroidetes ratio. Deferribacteres and Synergistetes also increased in the DIO
animals. In contrast, these animals exhibited a significant decrease in the content of Cyanobacteria
and Actinobacteria. Treatment with MaR1 was not able to reverse the dysbiosis caused by obesity
on the most abundant phyla. However, the MaR1 treatment increased the content of P. xylanivorans,
which have been considered to be a promising probiotic with healthy effects on gut inflammation.
Finally, a positive association was found between the Deferribacteres and Il-1β expression, suggesting
that the increase in Deferribacteres observed in obesity could contribute to the overexpression of
inflammatory cytokines in the colonic mucosa. In conclusion, MaR1 administration ameliorates
the inflammatory state in the colonic mucosa and partially compensates changes on gut microbiota
caused by obesity
Effects of Maresin 1 (MaR1) on Colonic Inflammation and Gut Dysbiosis in Diet-Induced Obese Mice
The aim of this study was to characterize the effects of Maresin 1 (MaR1), a DHA-derived
pro-resolving lipid mediator, on obesity-related colonic inflammation and gut dysbiosis in diet-induced
obese (DIO) mice. In colonic mucosa of DIO mice, the MaR1 treatment decreased the expression
of inflammatory genes, such as Tnf-α and Il-1β. As expected, the DIO mice exhibited significant
changes in gut microbiota composition at the phylum, genus, and species levels, with a trend to a
higher Firmicutes/Bacteroidetes ratio. Deferribacteres and Synergistetes also increased in the DIO
animals. In contrast, these animals exhibited a significant decrease in the content of Cyanobacteria
and Actinobacteria. Treatment with MaR1 was not able to reverse the dysbiosis caused by obesity
on the most abundant phyla. However, the MaR1 treatment increased the content of P. xylanivorans,
which have been considered to be a promising probiotic with healthy effects on gut inflammation.
Finally, a positive association was found between the Deferribacteres and Il-1β expression, suggesting
that the increase in Deferribacteres observed in obesity could contribute to the overexpression of
inflammatory cytokines in the colonic mucosa. In conclusion, MaR1 administration ameliorates
the inflammatory state in the colonic mucosa and partially compensates changes on gut microbiota
caused by obesity